✅ No sanctions, screening, insolvency or control red flags found in the public sources we cover. (Absence of a flag is not a guarantee — see methodology.)
GENOSCIENCE PHARMA
5599 · RC 438910747 · Active since 2001
Overview
GENOSCIENCE PHARMA is a 5599 registered , France, since 2001. The company operates in the 7211 sector. With reported revenue of 506K EUR in 2023. Its TraceComp score of 77 (B+) indicates solid fundamentals and low apparent risk. With 24 years of operations, the company has an established track record in its market.
Company Information
- Registration Number
- 438910747
- Legal Form
- 5599
- Registered
- 2001-07-06
Financial Profile
Latest filed accounts: FY 2023 · most recent available in public filings
Multi-year financials & ratios
5 years of filed accounts on file — full balance sheets, current ratio, debt-to-equity, net margin and the Altman-Z distress trend.
What’s in the full report
- Financial statements — revenue, assets, equity & margins for every year on file (multi-year trend where available)
- Key ratios & credit score — liquidity, leverage & profitability ratios plus our 0–100 score with a factor-by-factor breakdown
- Insolvency & legal events — collective proceedings and adverse filings (where on record)
- Charges & secured lending — registered charges and the creditors entitled (where filed)
- Sanctions & screening — company-level watchlist & adverse signals
- Sector benchmark & peers — how the company compares to its sector and nearest peers
- Innovation & EU funding — patents, research output & EU research funding received (where applicable)
Officers & Management
5 officers/directors on file — names, roles, appointment & resignation dates.
| Name | Role | Status |
|---|---|---|
| BRUNO CHALOM SAYADA | role 65 | Current |
What’s in the full report
- Financial statements — revenue, assets, equity & margins for every year on file (multi-year trend where available)
- Key ratios & credit score — liquidity, leverage & profitability ratios plus our 0–100 score with a factor-by-factor breakdown
- Insolvency & legal events — collective proceedings and adverse filings (where on record)
- Charges & secured lending — registered charges and the creditors entitled (where filed)
- Sanctions & screening — company-level watchlist & adverse signals
- Sector benchmark & peers — how the company compares to its sector and nearest peers
- Innovation & EU funding — patents, research output & EU research funding received (where applicable)
Research Output
Active research organization. 150 publications · 5,470 citations · h-index 41 in the global scholarly record (OpenAlex — 82.9M papers). Top fields by publication volume: Medicine (60%) · Mathematics (17%) · Immunology and Microbiology (14%).
See full research profile — top researchers & publications →
Source: OpenAlex (CC0). Objective publication & citation counts.
Patent Portfolio
Active patent holder. 4 patents · 4 active · 4 granted in the USPTO/EPO record.
See full patent portfolio — most-cited inventions & inventors →
Source: USPTO / EPO open patent data. Objective bibliographic counts.
Risk Signals
No adverse legal events have been recorded for this company.
- Revenue up 88% year-on-year
- Net loss reported in FY 2023
- Altman Z-Score in the distress zone — elevated insolvency risk on the model
Data Sources & Freshness
Data sourced from: bulk register.